Adult medulloblastoma in an Australian population
暂无分享,去创建一个
A. Abou-Hamden | E. Hovey | H. Gan | A. Anazodo | Sarah A. Cain | L. Cher | R. Harrup | S. Parakh | G. Pranavan | K. Westcott | E. Ahern | James R. Whittle | J. Lynam | Amy Davies | Daniela Roos | Peter K.H. Lau | Sowmya Cheruvu | A. Pullar | C. Gzell | Po-ling Inglis | A. Davies | A. Abou‐Hamden | James Lynam | Sarah A Cain | D. Roos | J. Whittle | Amal Abou-Hamden
[1] K. Aldape,et al. The Alliance AMBUSH Trial: Rationale and Design , 2022, Cancers.
[2] A. Brandes,et al. Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment? , 2022, Cancers.
[3] H. Arai,et al. Bevacizumab, irinotecan, and temozolomide with re-irradiation in adult recurrent medulloblastoma: A first case report , 2021 .
[4] M. Weller,et al. Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 , 2021, Cancers.
[5] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[6] K. Pajtler,et al. How we treat medulloblastoma in adults , 2021, ESMO open.
[7] D. Indelicato,et al. Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes , 2021, Journal of Neuro-Oncology.
[8] M. Martínez-García,et al. SEOM clinical guideline for management of adult medulloblastoma (2020) , 2021, Clinical and Translational Oncology.
[9] P. Wen,et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] M. Gilbert,et al. Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] A. Silvani,et al. Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology) , 2020, Neurological Sciences.
[12] M. Weller,et al. Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study , 2020, Journal of Neuro-Oncology.
[13] A. Cervantes,et al. Personalized Medicine: Recent Progress in Cancer Therapy , 2020, Cancers.
[14] M. J. van den Bent,et al. EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. , 2019, The Lancet. Oncology.
[15] T. Gupta,et al. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping , 2019, Journal of Neuro-Oncology.
[16] G. Noël,et al. Medulloblastoma: optimizing care with a multidisciplinary approach , 2019, Journal of multidisciplinary healthcare.
[17] David T. W. Jones,et al. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) , 2018, Neuro-oncology.
[18] Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017 , 2018, Asia-Pacific journal of clinical oncology.
[19] T. MacDonald,et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma , 2017, Neuro-oncology.
[20] V. Ramaswamy,et al. Medulloblastoma in adults: they're not just big kids. , 2016, Neuro-oncology.
[21] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[22] Gary D. Bader,et al. Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.
[23] Michael C. Rusch,et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Indelicato,et al. Late toxicity following craniospinal radiation for early-stage medulloblastoma , 2014, Acta oncologica.
[25] Roland Eils,et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.
[26] M. Rosenthal,et al. Local perspective on a rare brain tumour: adult medulloblastoma , 2013, Internal medicine journal.
[27] T. Pietsch,et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. , 2013, European journal of cancer.
[28] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[29] S. Croul,et al. Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Kavan,et al. Characteristics and outcomes of medulloblastoma in adults , 2008, Pediatric blood & cancer.
[31] J. Buckner,et al. High‐dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system , 2008, Cancer.
[32] R. Lai. Survival of patients with adult medulloblastoma , 2008, Cancer.
[33] P. Burger,et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Rorke,et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Souweidane,et al. Long-term outcomes of adult medulloblastoma patients treated with radiotherapy , 2017, Journal of Neuro-Oncology.
[36] M. Rosenblum,et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.